Assuntos
Anticorpos Monoclonais/efeitos adversos , Antineoplásicos/efeitos adversos , Síndrome do Desconforto Respiratório/induzido quimicamente , Anticorpos Monoclonais Humanizados , Neoplasias da Mama/tratamento farmacológico , Evolução Fatal , Feminino , Humanos , Pessoa de Meia-Idade , Fatores de Tempo , TrastuzumabAssuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Anticoagulantes/efeitos adversos , Equimose/induzido quimicamente , Sulfonamidas/efeitos adversos , Varfarina/efeitos adversos , Idoso , Celecoxib , Monitoramento de Medicamentos/métodos , Monitoramento de Medicamentos/enfermagem , Equimose/enfermagem , Humanos , Masculino , Avaliação em Enfermagem/métodos , PirazóisAssuntos
Anticoagulantes/efeitos adversos , Antioxidantes/efeitos adversos , Transtornos da Coagulação Sanguínea/induzido quimicamente , Cardiomiopatias/tratamento farmacológico , Ubiquinona/efeitos adversos , Varfarina/efeitos adversos , Coenzimas , Interações Medicamentosas , Humanos , Masculino , Pessoa de Meia-Idade , Ubiquinona/análogos & derivadosAssuntos
Antirreumáticos/efeitos adversos , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Imunoglobulina G/uso terapêutico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Sepse/induzido quimicamente , Adulto , Rotulagem de Medicamentos , Etanercepte , Feminino , Humanos , Avaliação em Enfermagem , Estados Unidos , United States Food and Drug AdministrationRESUMO
ICDs have reduced mortality from SCD to 2% per year, which is a record unmatched by any other form of therapy. With continued evolution, ICD systems should become easier to implant, smaller, more effective in managing a variety of abnormal rhythms, and more comfortable for the patient. Implementation of technological innovations in future-generation devices should continue to extend the frontiers as clinicians consider ICDs for an expanding range of therapeutic applications.
Assuntos
Desfibriladores Implantáveis/história , Arritmias Cardíacas/história , Eletrocardiografia/história , Desenho de Equipamento/história , História do Século XX , HumanosAssuntos
Antialérgicos/efeitos adversos , Antidepressivos de Segunda Geração/efeitos adversos , Astemizol/efeitos adversos , Fluoxetina/efeitos adversos , Taquicardia/induzido quimicamente , Adulto , Interações Medicamentosas , Humanos , Masculino , Estados Unidos , United States Food and Drug AdministrationRESUMO
The diurnal incidence of supraventricular tachycardia (SVT), including atrial fibrillation and atrial flutter, has been quantified by examining 7,891 cases of symptomatic arrhythmia in 5,869 patients assigned to ambulatory monitoring using electrocardiographic event recorders with transtelephonic reporting. The probability of occurrence of SVT was found to be high and moderately variable throughout the normally active hours of the day between 8 A.M. and 8 P.M. and to be uniformly low during the inactive hours between 1 and 5 A.M. Age-related peaks within the active phase were independently associated with the older half of the study population (9 A.M.) and with the younger half (6 P.M.). The daily incidence of SVT is primarily characterized by 2 states of activity, active and quiescent. Quiescence of SVT is associated with normal sleep and inactivity.
Assuntos
Ritmo Circadiano , Taquicardia Supraventricular/fisiopatologia , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Fibrilação Atrial/fisiopatologia , Flutter Atrial/fisiopatologia , Eletrocardiografia Ambulatorial , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Two years after implantation of an ICD with epicardial patch leads, a patient presented with hemoptysis. The posterior left ventricular patch was found to have eroded into lingular segmental bronchus. During thoracotomy, the hardware was removed and the bronchus successfully repaired.
Assuntos
Brônquios , Desfibriladores Implantáveis/efeitos adversos , Migração de Corpo Estranho , Idoso , Migração de Corpo Estranho/diagnóstico por imagem , Migração de Corpo Estranho/cirurgia , Humanos , Masculino , Tomografia Computadorizada por Raios XRESUMO
This prospective multicenter study was conducted under the Food and Drug Administration Investigational Device Exemption to evaluate the safety and efficacy of the combination of the Cadence implantable defibrillator (Ventritex, Inc.) and 60-series Endotak C leads (Cardiac Pacemakers, Inc.). Implantation was attempted in 148 patients with hemodynamically compromising ventricular tachycardia or fibrillation (VF), or with pace-terminable ventricular tachycardia. The system was successfully implanted in 97% of patients, with 96% of implants in a transvenous-lead-alone configuration. At implantation, the defibrillation threshold was 455 +/- 94 V (14 +/- 6 J) for lead-alone patients and 532 +/- 40 V (19 +/- 3 J) for those requiring a subcutaneous patch. VF conversion efficacy was reconfirmed in patients who underwent a 3-month chronic induction study. The system successfully detected all 763 induced arrhythmias and terminated 99.5% of them; after system modification, successful conversion was demonstrated in the 2 patients who initially had induced episodes requiring external defibrillation (1 lead revision; 1 reprogramming). All spontaneous episodes were terminated with an implantable-cardioverter defibrillator. Postshock VF redetection times were significantly shorter than initial detection times (4.5 +/- 1.8 seconds detection, 2.1 +/- 0.7 seconds redetection; p<0.0001). During an 8-month mean follow-up (range 1 to 31 months), 2 unwitnessed deaths were classified as sudden cardiac deaths, and 11 patients experienced a total of 12 complications, none of which was associated with the Cadence-Endotak combination.